Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

57 results about "Beta globulins" patented technology

Beta globulins are a group of globular proteins in plasma that are more mobile in alkaline or electrically charged solutions than gamma globulins, but less mobile than alpha globulins.

Methods of Purifying Antibodies

ActiveUS20130317200A1Rapid and efficient separationFavorable manufacturing characteristicHybrid immunoglobulinsFermentationHeavy chainBinding site
The invention provides methods of purifying antibodies using various antibody-specific purification media to rapidly and efficiently separate mixtures of antibodies, antibody fragments and / or antibody components to isolate a desired antibody product from the mixture. The invention relates to the purification of bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, e.g., antibodies composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain, including antibodies of different specificities that share a common heavy chain. The invention also provides the methods of efficiently purifying intact antibodies by separating the intact antibody from non-intact antibodies including free light chains.
Owner:NOVIMMUNE

Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions

The present invention provides fully human antibodies in a transgenic animal of a desired isotype in response to immunization with any virtually any desired antigen. The human immunoglobulin heavy chain transgene in the foregoing animals comprises a human constant region gene segment comprising exons encoding the desired heavy chain isotype, operably linked to switch segments from a constant region of a different heavy chain isotype, i.e., a non-cognate switch region. Said additional constant region segment comprises a switch region and human constant region coding segment, wherein the constant region coding segment is operably linked to a switch region that it is not normally associated with, i.e., a non-cognate switch region. In the transgenes of the invention, the non-cognate switch region may be a switch region from a different species than the constant region coding segment. The switch region and membrane exons of the invention may comprise a human gamma-2 constant region and the secreted constant region exons are from a human gamma-1 or a human gamma-4 constant region.
Owner:AMGEN FREMONT INC

Method for improving gene targeting efficiency and method for carrying out in-situ repair on base on beta-globulin gene locus

InactiveCN106244555AShorten the construction experiment cycleHigh miss rateNucleic acid vectorVector-based foreign material introductionGene targetsGene Modification
The invention provides a method for improving the gene targeting efficiency and a method for carrying out in-situ repair on the base on a beta-globulin gene locus. The method for improving the gene targeting efficiency comprises the following steps of: S10, determining a gene locus to undergo in-situ repair; and S20, introducing a CRISPR / Ca system to cleave editing lotus DNA to cause DNA damage and simultaneously providing a repair template segment. Based on the deficiency of existing gene modification, the gene modification efficiency, the timeliness and the modification quality are improved after single-stranded oligonucleotides (ss ODNs) and a small molecule compound participate in a CRISPR / Cas9 gene modification system.
Owner:THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY

Method for determining content of beta-lactoglobulin in milk powder

The invention discloses a method for determining the content of beta-lactoglobulin in milk powder. The method comprises the following steps: (1) selecting TK-11 as a specific peptide fragment and conducting beta-lactoglobulin quantification; (2) synthesizing the peptide fragment, and conducting isotope labeling on the peptide fragment; (3) accurately quantifying the synthesized standard peptide fragment by adopting an isotope dilution mass spectrography; (4) conducting sample treatment and enzyme digestion; (5) hygroplasm analysis, namely filtering the solution after enzyme digestion through a filter film, and then carrying out selective ion scanning analysis on the filtrate by adopting mass spectrography; and (6) calculating according to a formula, so as to complete the determination on the content of beta-lactoglobulin in milk powder. By adopting the method, determination results are accurate and reasonable.
Owner:NAT INST OF METROLOGY CHINA +1

Methods of purifying antibodies

The invention provides methods of purifying antibodies using various antibody-specific purification media to rapidly and efficiently separate mixtures of antibodies, antibody fragments and / or antibody components to isolate a desired antibody product from the mixture. The invention relates to the purification of bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, e.g., antibodies composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain, including antibodies of different specificities that share a common heavy chain. The invention also provides the methods of efficiently purifying intact antibodies by separating the intact antibody from non-intact antibodies including free light chains.
Owner:NOVIMMUNE

Neisseria gonorrhoeae, Chlamydia trachomatis and Ureaplasma urealyticum detection kits

ActiveCN102277429AWill not affect the results of the hybridizationGood synchronizationMicrobiological testing/measurementBiotinA-DNA
The invention discloses a gonococcus, chlamydia trachomatis and ureaplasma urealyticum detection kit. The detection kit comprises a gene chip (1) and various primers (2), wherein the gene chip carries (i) nucleotide probes of different pathogens, (ii) a biotin point-labeled DNA (deoxyribonucleic acid) sequence and (iii) a DNA sequence carrying beta-globulin encoding part; the nucleotide probes are a sequence of SEQ ID Nos:1-3 or a sequence complementary to SEQ ID Nos:1-3; the biotin point-labeled DNA sequence is SEQ ID No.4; the DNA sequence carrying beta-globulin encoding part serving as an internal control point is SEQ ID No.5; and various primers are used for amplifying the DNA sequences in a clinical sample, and have DNA sequences of SEQ ID Nos.6-11. The kit can quickly and accuratelydetect infections of gonococcus, chlamydia trachomatis and ureaplasma urealyticum, and has magnificent meaning to pathogen detection.
Owner:GUANGDONG HYBRIBIO BIOTECH CO LTD

Genetic testing kit for infected bacteria in cerebrospinal fluid

The invention discloses a genetic testing kit for infected bacteria in cerebrospinal fluid. The genetic testing kit comprises (1) a gene chip and (2) a primer, wherein the gene chip is provided with a. a probe used for detecting 10 bacterial colonies, b. a DNA (Deoxyribonucleic Acid) sequence labeled with biotin points, and c. a DNA sequence with a coding beta-globulin, the probe is SEQ ID Nos: 1-12, the DNA sequence labeled with the biotin points is SEQ ID No.13, and the DNA sequence with the coding beta-globulin is SEQ ID No.14 as an internal locus of control; and the primer includes a first primer used for amplifying 16S rRNA conserved sequences of a majority of common bacteria, a second primer used for amplifying 23S rRNA conserved sequences of the bacteria, and a third primer used for amplifying the internal locus of control, DNA sequences of first primer are SEQ ID Nos: 15-17, DNA sequences of the second primer are SEQ ID Nos.18-19, and DNA sequences of the third primer are SEQ ID Nos.20-21. The genetic testing kit for the infected bacteria in the cerebrospinal fluid, disclosed by the invention, can be used for quickly and accurately detecting 10 common bacteria in the cerebrospinal fluid, and has an important significance in correctly diagnosing and treating an intracranial infector in time.
Owner:GUANGDONG HYBRIBIO BIOTECH CO LTD

Nucleic acid aptamer for combining human beta-microglobulin

The invention discloses a short-chain nucleotide aptamer with high specificity and high affinity of beta-microglobulin and a screening method of the aptamer. The nucleotide aptamer provided by the invention comprises DNA (deoxyribonucleic acid) segments of nucleic acids shown by any one from a sequence 1 to a sequence 10. The preparation method of the nucleotide aptamer comprises the steps of designing and synthesizing a random single-chain nucleotide library, and screening the nucleotide aptamer of the beta-microglobulin. The nucleic acid aptamer disclosed by the invention is used for identifying a combined target, so that the nucleic acid aptamer is favorable for rapid determination of the beta-microglobulin.
Owner:杭州耀洲生物科技有限公司 +1

Rapid and sensitive genotype identification and nucleic acid detection

The invention discloses a method, primer, probe and kit for identifying various gene mutations or substance genetic typing. In one embodiment, the disease is pathogenic. In the other embodiment, the invention is applied to detection of multidrug-resistant Mycobacterium tuberculosis, hepatitis B virus, beta-globulin mutation, thrombophilia related mutation; or various sexually transmitted pathogens, consisting of Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum, Herpes simplex virus 1 , Herpes simplex virus 2, Human papillomavirus type 6, and Human papillomavirus type 1.
Owner:DIAGCOR LIFE SCI LTD

Typing detection kit for Candida albicans

The invention discloses a typing detection kit for Candida albicans. The typing detection kit comprises a gene chip and various primers. The gene chip is provided with 13 different types of nucleotide sequence probes for the Candida albicans, a DNA sequence marked with biotin points and a DNA sequence with a coding beta-globulin part, wherein the probes are in the sequences of SEQ ID Nos: 1-13 or sequences complementary with the SEQ ID Nos: 1-13, the DNA sequence with the biotin points is SEQ ID No. 14, and the DNA sequence with the coding beta-globulin part is SEQ ID No. 15. The various primers are in the sequences of SEQ ID Nos: 16-21. By means of the typing detection kit for the Candida albicans, a typing joint detection platform for detecting the Candida albicans is provided, synchronous joint detection can be achieved, the detection of specificity can be enhanced, the cost can be lowered, the detection time can be shortened, and the typing detection kit has great significance for carrying out clinic early diagnosis and population screening for the Candida albicans.
Owner:上海凯普医学检验所有限公司 +2

Rapid genotyping analysis and kits thereof

The present invention provides methods, primers, probes, and kits for identifying gene mutation or material genotyping. In one embodiment, the materials are disease-causing agents. In another embodiment, the present invention is applied to detecting multidrug-resistant mycobacterium tuberculosis, hepatitis B virus, beta-globulin mutation, thrombosis-related mutations; or multiple sexually transmitted diseases causing agents, including but not limited to, trichomonas vaginalis, chlamydia, neisseria gonorrhoeae, mycoplasma, mycoplasma hominis, ureaplasma urealyticum, Mycelia, Treponema pallidum, Herpes simplex virus type 1 and type 2 and human papilloma virus type 6 and type 11.
Owner:DIAGCOR LIFE SCI LTD

Cell

The present invention provides a cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) a polypeptide capable of co-localizing a beta-2 microglobulin component of a MHC class I molecule with an intracellular signalling domain within the cell.
Owner:AUTOLUS LIMIED

Nucleic acid aptamer capable of specifically recognizing beta-lactoglobulin and application of nucleic acid aptamer

The invention belongs to the fields of biology and medicine, and particularly relates to a nucleic acid aptamer capable of specifically recognizing beta-lactoglobulin and application of the nucleic acid aptamer. The nucleic acid aptamer has a sequence shown in SEQ ID NO.1; or a sequence which has 60% of homology or above with the sequence shown in the SEQ ID NO.1 and can specifically recognize thebeta-lactoglobulin; or a sequence which is derived from the sequence shown in the SEQ ID NO.1 and can specifically recognize the beta-lactoglobulin. The nucleic acid aptamer can specifically bind theallergen beta-lactoglobulin in cow milk and milk products, and a new tool is provided for high-sensitivity and low-cost detection of the allergen beta-lactoglobulin.
Owner:JIANGNAN UNIV

Fluorescence method for detecting beta-lactoglobulin based on quantum dot-nucleic acid aptamer-graphene oxide

The invention relates to a fluorescence method for detecting beta-lactoglobulin based on quantum dot-nucleic acid aptamer-graphene oxide. Carboxyl modified water-soluble quantum dots are used as a fluorophore; an amino-modified aptamer is used as a recognition molecule; graphene oxide (GO) is used as a quenching agent, a novel composite nano fluorescent probe is constructed, a reactant is shot andimaged under an ultraviolet lamp, and quantitative detection data is obtained by using image J image processing software, thereby realizing high-sensitivity detection of target molecule beta-lactoglobulin.
Owner:TIANJIN UNIV OF SCI & TECH

Sargassum thunbergii lectin and preparation method thereof

The invention discloses a sargassum thunbergii lectin and a preparation method thereof, wherein the preparation method of the sargassum thunbergii lectin is characterized by selecting sargassum thunbergii as a raw material, carrying out lyophilization, pulverization, immersion, centrifugation, ammonium sulfate fractionation, DEAE-52 ion-exchange chromatography and SephadexG-200 gel filtration chromatography, thus producing the sargassum thunbergii lectin with a molecular weight of 17 kD. The sargassum thunbergii lectin of the invention can agglutinate a wide range of cells, has agglutinative functions for erythrocytes of rabbits, dogs, sheep, crucians, chickens and humans (A, B, AB), and the like, wherein minimum concentrations of agglutination reactions with rabbit and chicken erythrocytes are 4.4mg / ml and 0.55 mg / ml respectively, and shows hemagglutinin activity for rabbit erythrocytes even after heating treatment at 100 DEG C for 30 min (the activity decreases by 75%). A sugar inhibition experiment shows that the sargassum thunbergii lectin is only inhibited by glycoproteins as bovine thyroglobulin and gamma-globulin, and the minimum inhibition concentrations are 1.25 mg.mL<-1> and 2.5 mg.mL<-1> respectively.
Owner:DALIAN OCEAN UNIV +1

Prediction method and prediction system for gamma globulin non-reactive Kawasaki disease

The invention provides a prediction method and system for a gamma globulin non-reactive Kawasaki disease. The method comprises the following steps of collecting 21 original parameters of an SVM model, wherein the original parameters for modeling include gender, age, fever time during doctor seeing, clinical classification, a CRP detection value, a WBC value, a PLT value, an Hb value, an ALT value, an AST value, an ALB value, gamma globulin usage time and clinical diagnosis symptom indexes, and the clinical diagnosis symptom indexes include conjunctival congestion, rash, cracked lips, strawberry-like tongue, neck lymphadenectasis, hand and foot scleredema, digit desquamation, perianal desquamation and vaccinated scar redness and swelling; performing discretization processing on the original parameters to obtain SVM eigenvalues corresponding to the original parameters; and building the SVM model by taking the SVM eigenvalues as basic data, and predicting gamma globulin non-reactive complications of the Kawasaki disease through the SVM model. According to the prediction method and system, patients can be subjected to early intervention treatment, thereby facilitating coronary artery injury recovery; and the prediction method and system has important significance and value for diagnosis and treatment of the Kawasaki disease.
Owner:SOOCHOW UNIV AFFILIATED CHILDRENS HOSPITAL +1

Method for separating [alpha]-lactalbumin and [beta]-lactoglobulin

The invention discloses a method for separating [alpha]-lactalbumin and [beta]-lactoglobulin. The present invention relates to a method for providing an alpha-lactalbumin fraction and a beta-lactoglobulin fraction from a whey material obtained from milk, the method comprising the steps of: (i) providing the whey material; (ii) contacting the whey material with a chromatographic support allowing beta-lactoglobulin to be retained by the chromatographic support; (iii) obtaining a permeate fraction from the chromatographic support comprising the alpha-lactalbumin fraction; (iv) optionally washing the chromatographic support; and (v) obtaining a retentate fraction from the chromatographic support comprising the beta-lactoglobulin fraction; wherein the whey material provided in step (i) has been depleted, or substantially depleted from at least one whey protein, such as at least 2 whey proteins, e.g. at least 3 whey proteins.
Owner:UPFRONT CHROMATOGRAPHY

Anti-human beta2-MG antibody and application thereof

The invention relates to a novel anti-human beta2-microglobulin antibody and application thereof, and belongs to the field of immunochemistry. Various antibodies are prepared by the invention, matching screening is performed, and an antibody combination (BM12 and BM17) with the sensitivity and the specificity meeting the requirements is obtained; meanwhile, the mass production is convenient; the requirements of large-scale clinic application in future can be met. The antibody combination is subjected to detection system debugging and optimization work to achieve the effect of simple and convenient operation. The industrialized application of colloidal gold rapid test paper card of human beta2-microglobulin with the sensitivity, specificity and relevant detection performance meeting the requirements of human-clinic sample detection can be realized.
Owner:ZONHON BIOPHARMA INST

Anti-human beta2-microglobulin antibody and application thereof

The invention relates to a novel anti-human beta2-microglobulin antibody and application thereof, and belongs to the field of immunochemistry. Various antibodies are prepared, paired and screened, andthe antibody combination (BM12 and BM17) is obtained, wherein the sensitivity and the specificity of the antibody combination can meet requirements. Mass production is facilitated, and future requirements of large-scale clinical application can be met. The antibody combination is subjected to debugging and optimizing of a detection system, and industrial application of collaurum rapid test papercards of human beta2-microglobulin is obtained, wherein the collaurum rapid test paper cards are convenient to operate, and the sensitivity, the specificity and correlation detection performance of the collaurum rapid test paper cards can meet human clinical sample detection.
Owner:ZONHON BIOPHARMA INST

Recombinant lentivirus vector for treating beta-globulin afunction, preparation method and application

The application discloses a recombinant lentivirus vector for treating beta-globulin afunction, a preparation method and application. A gene element of the recombinant lentivirus vector disclosed by the application is composed of a left side lentivirus long terminal repeat, a lentivirus counter-response element, a center poly-purine sequence, a gene locus regulating and controlling sequence of a beta-globulin gene, a beta-globulin gene, of which 87-th threonine is mutated into glutamine, and a right side lentivirus long terminal repeat which are connected in order. According to the recombinant lentivirus vector disclosed by the application, through optimizing and improving the gene element, the gene transduction efficiency is increased, and the beta-globulin gene can be efficiently expressed during erythroid differentiation of hemopoietic stem cells, so that the consumption of viruses can be effectively lowered, and the treatment cost is reduced while the safety is improved. The recombinant lentivirus vector disclosed by the application provides a novel treatment tool and scheme for beta-thalassemia and sickle cell anemia caused by the beta-globulin afunction.
Owner:深圳市禾沐基因生物技术有限责任公司

Hemoglobinopathy treatment effectiveness prediction method

The invention relates to a method for treating hemoglobinopathy in an individual. The method comprises the following steps: (a), an evaluation step; the evaluation step comprises the process of evaluating the ability to generate the required level of gamma-globulin or fetal hemoglobin after differentiation of a first population of modified CD34 positive hematopoietic stem / progenitor cells, whereinthe first population of modified CD34 positive HSPC is derived from the individual and modified to reduce the BCL11A function; and (b), a treatment step; the treatment step comprises the process of administering a second population of modified CD34 positive HSPC to the individual; and the modified CD34 positive HSPC is derived from the individual and modified to reduce the BCL11A function. Meanwhile, the invention also relates to a method for treating hemoglobinopathy in the individual, a method of selecting an individual suffering from hemoglobinopathy for treatment with the second population of modified CD34 positive HSPC, and a method of determining whether an individual suffering from hemoglobinopathy is suitable or not suitable for treatment with the second population of modified CD34 positive HSPC derived from the individual and modified to reduce the BCL11A function.
Owner:EDIGENE GUANGZHOU INC

Method for determining content of beta2-microglobulin

PendingCN114460190AEasy to measureComponent separationPeritoneal EffusionFluid phase
The invention discloses a method for determining the content of beta2-microglobulin. The method comprises the following steps: 1, preparing a test solution; the method comprises the following steps: taking 1ml of a sample, putting the sample into a 100ml measuring flask, adding a 6mol / L urea solution to a scale, standing at room temperature for 1 hour, and filtering by using a 0.45 mu m filter membrane, thereby obtaining the target product. 2, preparing a reference substance solution; the method comprises the following steps: taking a proper amount of a beta 2-microglobulin reference substance, putting the reference substance into a 100ml measuring flask, adding a 6mol / L urea solution to a scale, and standing at room temperature for 1 hour, so that each 1ml of the prepared solution contains 10mu g of beta 2-microglobulin; step 3, determining according to a high performance liquid chromatography; according to the present invention, the high performance liquid chromatography is adopted to perform determination, such that the beta 2-microglobulin result in the urine and the peritoneal effusion of the patient can be rapidly and conveniently determined, the important significance is provided for the monitoring of the beta 2-microglobulin in the patient body, and the important significance is provided for the artificial kidney research and development.
Owner:西安乐析医疗科技有限公司

Preparation method and application of photoelectrochemical biosensor for detecting beta-lactoglobulin

The invention relates to a preparation method of a photoelectrochemical immunosensor for detecting dairy allergen beta-lactoglobulin, and belongs to the technical fields of functional nano materials, food analysis and photoelectrochemical biosensing. A CdWO4-TiO2 heterojunction composite material is fixed on the surface of an ITO (Indium Tin Oxide) electrode, CdS quantum dots are used for sensitization to enhance absorption of light, the CdS quantum dots are used as a connecting agent to fix an allergen beta-lactoglobulin antibody, the photocurrent response and sensitivity are effectively improved, through a layer-by-layer assembly method, by utilizing the good photoelectric activity of the CdWO4-TiO2 heterojunction sensitized by the CdS quantum dots and the specific binding between the beta-lactoglobulin and the beta-lactoglobulin antibody, the ultra-sensitive detection of the beta-lactoglobulin is realized, and the method has important significance on the analysis and detection application of the beta-lactoglobulin in dairy products.
Owner:SHANDONG UNIV OF TECH

A cell cryopreservation medium for dendritic cells

ActiveCN107306939BMaintain immune activityImmune activity helps maintainDead animal preservationDendritic cellImmunocompetence
The invention discloses a cell cryopreservation medium for dendritic cells. An effective amount of cryoprotective agents, cell stabilizers and anti-setting agents are added into RPMI-1640 culture medium and uniformly mixed to form the cell cryopreservation medium for the dendritic cells. The cryoprotective agent is dimethyl sulfoxide, and the cell stabilizer is human gamma globulin; the anti-setting agent is poly-L-lysine, and the molecular weight range of the poly-L-lysine is 30000 to 70000; and the volume percentage concentration of the dimethyl sulfoxide is 1 to 3 percent. When used for cryopreserving DCs, the cell cryopreservation medium disclosed by the invention can ensure the cryopreservation revival rate and immunocompetence of the DCs, and the cryopreservation revival rate and the immunocompetence are not significantly decreased within one year of cryopreservation; the human gamma globulin as the cell stabilizer can maintain the immunocompetence of the DCs; the poly-L-lysine as the anti-settling agent can prevent the human gamma globulin from settling to the bottom of the cell cryopreservation medium in the process of storage, and moreover, the poly-L-lysine has part of the effect of the cryoprotective agent, and can also help to maintain the immunocompetence of the DCs.
Owner:山东水发生命科学研究有限公司

Sargassum thunbergii lectin and preparation method thereof

The invention discloses a sargassum thunbergii lectin and a preparation method thereof, wherein the preparation method of the sargassum thunbergii lectin is characterized by selecting sargassum thunbergii as a raw material, carrying out lyophilization, pulverization, immersion, centrifugation, ammonium sulfate fractionation, DEAE-52 ion-exchange chromatography and SephadexG-200 gel filtration chromatography, thus producing the sargassum thunbergii lectin with a molecular weight of 17 kD. The sargassum thunbergii lectin of the invention can agglutinate a wide range of cells, has agglutinative functions for erythrocytes of rabbits, dogs, sheep, crucians, chickens and humans (A, B, AB), and the like, wherein minimum concentrations of agglutination reactions with rabbit and chicken erythrocytes are 4.4mg / ml and 0.55 mg / ml respectively, and shows hemagglutinin activity for rabbit erythrocytes even after heating treatment at 100 DEG C for 30 min (the activity decreases by 75%). A sugar inhibition experiment shows that the sargassum thunbergii lectin is only inhibited by glycoproteins as bovine thyroglobulin and gamma-globulin, and the minimum inhibition concentrations are 1.25 mg.mL<-1> and 2.5 mg.mL<-1> respectively.
Owner:DALIAN OCEAN UNIV +1

Alpha1 microglobulin trace detection method

The invention discloses an alpha1 microglobulin trace detection method, and relates to the technical field of biological detection methods. The method comprises the following steps: mixing a reagent a with a sample, adding a reagent b, and carrying out mixed incubation; adding a reagent c for mixing, and reading an absorbance value; after timing reaction, reading the absorbance value again; calculating the difference value of the two absorbance values, making a regression equation function curve of the difference value to the concentration of the alpha1 microglobulin, and substituting the difference value of the sample to be detected into the function curve to calculate the concentration of the alpha1 microglobulin; the reagent a comprising polyethylene glycol and sodium zinc ethylene diamine tetraacetate; the reagent b comprising polyvinylpyrrolidone and sodium chloride; the reagent c comprising polystyrene nanoparticles only marked with an alpha1 microglobulin monoclonal antibody and polystyrene nanoparticles only marked with an alpha1 microglobulin polyclonal antibody. According to the method, loss of alpha1 microglobulin in the sample in the detection process is effectively reduced, detection errors are reduced through specific reagent use and proportion adjustment, and sensitivity is improved.
Owner:JILIN UNIV FIRST HOSPITAL +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products